High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma

Ther Drug Monit. 2003 Feb;25(1):120-4. doi: 10.1097/00007691-200302000-00020.

Abstract

A rapid, sensitive, and specific high-performance liquid chromatography (HPLC) method for the simultaneous determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma is described. The analytes are quantified as the totals of their carboxylate and lactone form. The sample pretreatment consisted of a simple protein precipitation with acetonitrile-methanol (1:1, v/v), after which CPT-11 and SN-38 were quantitatively converted to their carboxylate form by adding 0.01 mol/L sodium tetraborate (pH, 9). Chromatography was carried out on a Zorbax SB-C18 column with fluorescence detection. The method has been validated, and stability tests under various clinically relevant conditions have been performed. The lower limit of quantification (LLOQ) was 5.0 ng/mL for CPT-11 and 0.5 ng/mL for SN-38. Standard concentration ranges were linear between 5 and 1,500 ng/mL for CPT-11 and between 0.5 and 100 ng/mL for SN-38. This assay is simple, rapid, and very useful for therapeutic monitoring of CPT-11 and SN-38.

MeSH terms

  • Antineoplastic Agents / blood*
  • Antineoplastic Agents / chemistry
  • Camptothecin / analogs & derivatives*
  • Camptothecin / blood*
  • Camptothecin / chemistry
  • Chromatography, High Pressure Liquid / methods
  • Humans
  • Irinotecan
  • Reproducibility of Results

Substances

  • Antineoplastic Agents
  • Irinotecan
  • Camptothecin